BR112022023048A2 - Tratamento de combinação de distúrbios hepáticos - Google Patents
Tratamento de combinação de distúrbios hepáticosInfo
- Publication number
- BR112022023048A2 BR112022023048A2 BR112022023048A BR112022023048A BR112022023048A2 BR 112022023048 A2 BR112022023048 A2 BR 112022023048A2 BR 112022023048 A BR112022023048 A BR 112022023048A BR 112022023048 A BR112022023048 A BR 112022023048A BR 112022023048 A2 BR112022023048 A2 BR 112022023048A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination treatment
- liver disorders
- fxr agonist
- disorders
- thkß
- Prior art date
Links
- 238000011284 combination treatment Methods 0.000 title abstract 3
- 210000004185 liver Anatomy 0.000 title abstract 2
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063024360P | 2020-05-13 | 2020-05-13 | |
| PCT/US2021/032085 WO2021231646A1 (en) | 2020-05-13 | 2021-05-12 | Combination treatment of liver disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023048A2 true BR112022023048A2 (pt) | 2022-12-20 |
Family
ID=78524975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023048A BR112022023048A2 (pt) | 2020-05-13 | 2021-05-12 | Tratamento de combinação de distúrbios hepáticos |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210379043A1 (https=) |
| EP (1) | EP4149452A4 (https=) |
| JP (1) | JP2023525571A (https=) |
| KR (1) | KR20230024277A (https=) |
| CN (1) | CN115811972A (https=) |
| AU (1) | AU2021273487A1 (https=) |
| BR (1) | BR112022023048A2 (https=) |
| CA (1) | CA3183413A1 (https=) |
| IL (1) | IL298144A (https=) |
| MX (1) | MX2022014238A (https=) |
| TW (1) | TW202207928A (https=) |
| WO (1) | WO2021231646A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3193057A1 (en) | 2020-08-25 | 2022-03-03 | Eli Lilly And Company | Polymorphs of an ssao inhibitor |
| KR20230142523A (ko) * | 2021-02-01 | 2023-10-11 | 마드리갈 파마슈티칼스, 인크. | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 |
| TWI845975B (zh) * | 2021-07-06 | 2024-06-21 | 中國大陸商甘萊製藥有限公司 | 用於治療肝臟疾病的聯合治療 |
| TW202315608A (zh) * | 2021-07-06 | 2023-04-16 | 中國大陸商甘萊製藥有限公司 | 用於治療肝臟疾病的聯合治療 |
| CN119013027A (zh) * | 2021-11-11 | 2024-11-22 | 拓臻制药公司 | 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合 |
| PE20241327A1 (es) * | 2021-11-11 | 2024-06-26 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-beta |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009001359A2 (en) * | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
| TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| KR102374499B1 (ko) * | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| JP7618384B2 (ja) * | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| WO2018208707A1 (en) * | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| ES3029158T3 (en) * | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| EP3844156A4 (en) * | 2018-08-30 | 2022-06-08 | Terns Pharmaceuticals, Inc. | TREATMENT OF HEPATIC DISORDERS |
| EA202190661A1 (ru) * | 2018-09-18 | 2021-08-13 | Метакрайн, Инк. | Агонисты фарнезоидного х-рецептора для лечения заболевания |
| CN111320609A (zh) * | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
-
2021
- 2021-05-12 US US17/318,994 patent/US20210379043A1/en not_active Abandoned
- 2021-05-12 CA CA3183413A patent/CA3183413A1/en active Pending
- 2021-05-12 JP JP2022568965A patent/JP2023525571A/ja active Pending
- 2021-05-12 CN CN202180047741.3A patent/CN115811972A/zh active Pending
- 2021-05-12 MX MX2022014238A patent/MX2022014238A/es unknown
- 2021-05-12 IL IL298144A patent/IL298144A/en unknown
- 2021-05-12 KR KR1020227043095A patent/KR20230024277A/ko not_active Ceased
- 2021-05-12 EP EP21803928.7A patent/EP4149452A4/en active Pending
- 2021-05-12 AU AU2021273487A patent/AU2021273487A1/en active Pending
- 2021-05-12 BR BR112022023048A patent/BR112022023048A2/pt unknown
- 2021-05-12 WO PCT/US2021/032085 patent/WO2021231646A1/en not_active Ceased
- 2021-05-13 TW TW110117355A patent/TW202207928A/zh unknown
-
2023
- 2023-01-20 US US18/157,216 patent/US20240000765A1/en not_active Abandoned
-
2024
- 2024-06-03 US US18/732,162 patent/US20240316025A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4149452A1 (en) | 2023-03-22 |
| TW202207928A (zh) | 2022-03-01 |
| AU2021273487A1 (en) | 2023-01-05 |
| IL298144A (en) | 2023-01-01 |
| US20240000765A1 (en) | 2024-01-04 |
| CN115811972A (zh) | 2023-03-17 |
| CA3183413A1 (en) | 2021-11-18 |
| MX2022014238A (es) | 2023-04-11 |
| JP2023525571A (ja) | 2023-06-16 |
| EP4149452A4 (en) | 2024-05-01 |
| US20210379043A1 (en) | 2021-12-09 |
| US20240316025A1 (en) | 2024-09-26 |
| KR20230024277A (ko) | 2023-02-20 |
| WO2021231646A1 (en) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023048A2 (pt) | Tratamento de combinação de distúrbios hepáticos | |
| BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112022022952A2 (pt) | Tratamento combinado de distúrbios hepáticos | |
| BR112021018739A2 (pt) | Composições e métodos para o tratamento de doenças ou distúrbios associados a kras | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
| BRPI0617165B1 (pt) | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos | |
| BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
| BR112016026560A2 (pt) | Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção | |
| BR112022010319A2 (pt) | Uso de bi853520 no tratamento de câncer | |
| BR112017009440A2 (pt) | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) | |
| BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
| BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
| BR112016004118A2 (pt) | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
| CO2024007225A2 (es) | Tratamiento de trastornos hepáticos con un agonista del thr-β | |
| BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
| BR112023003427A2 (pt) | Terapia com antagonista de lag-3 para carcinoma hepatocelular | |
| AR067395A1 (es) | Inhibicion de htra1 mediada por iarn para el tratamiento de la degeneracion macular | |
| BR112023016680A2 (pt) | Terapias de combinação com anticorpos anti-cd38 e parp ou inibidores de receptor de adenosina | |
| CL2022003511A1 (es) | Inhibidores de alk2 para el tratamiento de la anemia. | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| GT200600115A (es) | Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal |